Novartis Remibrutinib First Therapy to Achieve Phase III Primary Endpoint in Chronic Inducible Urticaria
February 19, 2026
February 19, 2026
BASEL, Switzerland, Feb. 19 -- Novartis, a pharmaceutical company, issued the following news release on Feb. 18, 2026:
* * *
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
* Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1
* Remibrutinib, a highly selective oral BTK inhibitor, was well-tolerated an . . .
* * *
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
* Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1
* Remibrutinib, a highly selective oral BTK inhibitor, was well-tolerated an . . .